VOR
Vor Biopharma·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 1
Consensus Rating "Buy"
Ample Liquidity
Significant Net Income Decline
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VOR
Vor Biopharma Inc.
A clinical stage cell therapy company to develop therapies for hematological malignancies patients
P.O. Box 380121, Cambridge, Massachusetts 02238
--
Vor Biopharma Inc., a wholly-owned subsidiary of PureTech Health LLC, was incorporated in Delaware on December 30, 2015. The company is a clinical-stage cell therapy company that combines novel patient engineering approaches and targeted therapies to provide a single company solution for patients with hematological malignancies. The company's proprietary platform leverages its expertise in hematopoietic stem cell biology, genome engineering and targeted therapy development to genetically modify HSCs to remove surface targets expressed by cancer cells. Vor is headquartered in Cambridge, Massachusetts.
Company Financials
EPS
VOR has released its 2025 Q3 earnings. EPS was reported at -121.63, versus the expected -4.1, missing expectations. The chart below visualizes how VOR has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
